New diabetes classifier
Dr. Scott Isaacs shared visuals of a Diabetes Classification Algorithm designed to flag non‑type 2 cases — think LADA and MODY — and map pharmacotherapy profiles across A1c, weight, and cardiorenal outcomes. (x.com) (x.com)
AACE published a 2026 update to its Type 2 diabetes management algorithm on March 17, 2026 that added a standalone "Diabetes Classification Algorithm." (read.qxmd.com) Scott D. Isaacs is listed as one of the task‑force authors on that AACE 2026 consensus statement. (waltersport.com) The new classification flow explicitly directs clinicians to confirm diagnostic criteria, check for a type‑2 phenotype, then trigger pathways to assess for type‑1 disease and “other types” (for example LADA or monogenic diabetes). (endocrinologyadvisor.com) The update also formalizes a "Profiles of Pharmacotherapy" section that lays out medication classes by expected A1c lowering, weight effects, and proven cardiorenal outcomes. (github.com) AACE’s move mirrors broader guideline activity this year: the ADA released its Standards of Care 2026 with expanded diagnostic and therapeutic figures and tables for medication selection. (diabetes.org) Latent autoimmune diabetes in adults (LADA) is estimated to represent roughly 2–12% of adult‑onset diabetes in published series, a prevalence that guidelines cite when recommending autoantibody and C‑peptide consideration for atypical cases. (diabetesjournals.org)
